

Washington, DC (Oct. 23, 2012)— In light of the recent meningitis outbreak that has claimed nearly two dozen lives and sickened hundreds more, Rep. John F. Tierney, Ranking Member of the Subcommittee on National Security, Homeland Defense and Foreign Operations, and Rep. Elijah E. Cummings, Ranking Member of the House Committee on Oversight and Government Reform, today [wrote](#) to the Government Accountability Office (GAO) to request an investigation of the pharmacy compounding industry and its oversight by federal and state agencies nationwide.

“In light of these tragic deaths, we need to know how many other companies are engaged in similar activity and whether they may be falling through the cracks between state and federal regulating agencies,” said Tierney. “Hundreds of people are now sick, families are scared, and some have even lost loved ones. If these cases are due to a lack of clarity in state or federal rules, we must ensure that reforms are made immediately.”

The request by Tierney and Cummings is intended to supplement a bipartisan investigation of the New England Compounding Center (NECC), which is based in Framingham, Massachusetts, currently being conducted by the House Committee on Energy and Commerce.

The full text of the letter is below:

The Honorable Gene L. Dodaro
Comptroller General of the United States
U.S. Government Accountability Office
441 G Street, NW
Washington, DC 20548

Dear Mr. Dodaro:

According to the Centers for Disease Control and Prevention, 23 people have died and more than 280 people have been sickened with fungal meningitis linked to tainted vials of an injectable steroid produced by the New England Compounding Center (NECC), based in Framingham, Massachusetts.[1] As the number of cases continues to climb, news accounts

report that NECC may have shipped more than 17,000 vials of this contaminated drug product to 23 states.[2]

It is our understanding that NECC was operating as a “pharmacy compounder,” meaning that it engaged in the process of mixing, combining, or altering ingredients for drug products on a customized basis for individual patients. While pharmacy compounders play an important role in providing patients with specialty products and dosages not easily available from manufacturers, the large volume of drug products sold by NECC raises questions about its proper classification. In addition, there are serious questions about the oversight of pharmacy compounders because they are subject to a patchwork of state and federal regulations, as well as conflicting legal opinions.

In 2003, the Government Accountability Office issued a report entitled State and Federal Oversight of Drug Compounding by Pharmacies that summarized the state of the law nine years ago. GAO reported:

[T]he ability of states to oversee and ensure the quality and safety of compounded drugs may be affected by state-specific factors such as the resources available for inspections and enforcement. FDA maintains that drug compounding activities are generally subject to FDA oversight, including its authority to oversee the safety and quality of new drugs. In practice, however, the agency generally relies on states to regulate the limited compounding of drugs as part of the traditional practice of pharmacy. In 1997, the Congress passed a law exempting drug compounders that met certain criteria from key provisions of the Federal Food Drug and Cosmetic Act (FDCA), including the requirements for the approval of new drugs. These exemptions, however, were nullified in 2002 when the United States Supreme Court ruled part of the 1997 law to be an unconstitutional restriction on commercial speech, which resulted in the entire compounding section being declared invalid.[3]

We are writing to request that GAO update its work on pharmacy compounding in the following ways:

1. We ask that GAO work with state Boards of Pharmacy as part of its own review to determine the size of the pharmacy compounding industry, including the number of licensed pharmacies currently engaging in compounding, as well as general information about the volume of drug products they sell on an annual basis.
2. We ask that GAO conduct a review of state laws and regulatory authority over pharmacy compounders, as well as specific enforcement actions, and describe any challenges they face

in effectively exercising authority over these entities.

3. We ask that GAO assess whether any gaps exist between state and federal regulatory systems in terms of the authorities exercised by state regulatory agencies and the Food and Drug Administration.

In addition to these issues, we would appreciate any additional information that GAO identifies as relevant to the administration and oversight of compound pharmacies. If you have any questions about this request, please contact Una Lee or Chris Knauer (202) 225-5051.

Sincerely,

Elijah Cummings
Ranking Member
Committee on Oversight and
Government Reform

John Tierney
Ranking Member
Subcommittee on National Security
Homeland Defense and Foreign Operations

cc: The Honorable Darrell E. Issa, Chairman
Committee on Oversight and Government Reform

The Honorable Jason Chaffetz, Chairman
Subcommittee on National Security, Homeland Defense and Foreign Operations

###